Several studies reported the efficacy of JAK inhibitors (e.g., ruxolitinib) both in CRLF2-rearranged (CRLF2-r) and other JAK activated Ph-like B-ALL cells and PDX models (20, 26, 27). Here, CRLF2 is linked to acute lymphoblastic leukemia.